Substituted oxazolidinones and their use in the field of blood coagulation

• US 7,592,339 B2
• Filed: 07/27/2006
• Issued: 09/22/2009
• Est. Priority Date: 12/24/1999
• Status: Expired due to Fees

• Current Assignee: Bayer Intellectual Property GmbH (Bayer AG)
• Original Assignee: Bayer Schering Pharma AG (Bayer AG)
• Inventors: Lampe, Thomas, Perzborn, Elisabeth, Schlemmer, Karl-Heinz, Straub, Alexander, Pohlmann, Jens, Pernerstorfer, Joseph, Rohrig, Susanne
• Primary Examiner(s): Anderson; Rebecca L
• Application Number:
  US11/460,529
• Publication Number:
  US 20060258724A1
• Time in Patent Office: 1,153 Days
• Field of Search: 514/236.8
• US Class Current: 514/236.8
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07D 333/38 Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• CPC Class Codes: C07D 409/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 413/10 linked by a carbon chain containing aromatic rings
• CPC Class Codes: C07D 413/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 413/14 containing three or more hetero rings
• CPC Class Codes: C07D 417/14 containing three or more hetero rings
• CPC Class Codes: C07D 495/04 Ortho-condensed systems
• CPC Class Codes: C07D 498/04 Ortho-condensed systems

Abstract

The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I)

processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.

Claims

1. A method for inhibiting thrombus formation comprising administering an effective amount of a compound of formula:

2. A method of claim 1, wherein said patient has a thromboembolism.

3. A method of claim 2 wherein said thromboembolism is a venous thromboembolism.

4. A method of claim 3 wherein said venous thromboembolism comprises pulmonary embolism.

5. A method of claim 3 wherein said venous thromboembolism comprises deep vein thrombosis.

6. A method for preventing thromboembolism comprising administering an effective amount of a compound of formula:

7. A method of claim 6, wherein said method prevents venous thromboembolism.

8. A method of claim 7, wherein said method prevents pulmonary embolism.

9. A method of claim 7, wherein said method prevents deep vein thrombosis.

10. A method for preventing a disorder due to thrombus formation selected from the group consisting of myocardial infarct, unstable angina, stroke, transitory ischaemic attacks, peripheral arterial occlusive disorders, pulmonary embolisms and deep venous thromboses comprising administering an effective amount of a compound of formula:

11. A method of claim 10, wherein said disorder is stroke.

12. A method of claim 10, wherein said disorder is myocardial infarct.

13. A method of claim 10, wherein said disorder is unstable angina.

14. A method of claim 10, wherein said disorder is peripheral arterial occlusive disorder.

15. A method of claim 10, wherein said disorder is pulmonary embolism.

16. A method of claim 10, wherein said disorder is deep venous thrombosis.

17. A method for treating a disorder selected from the group consisting of myocardial infarct, unstable angina, stroke, transitory ischaemic attacks, peripheral arterial occlusive disorders, pulmonary embolisms and deep venous thromboses comprising administering an effective amount of a compound of formula:

18. A method of claim 17 wherein said method treats pulmonary embolism.

19. A method of claim 17 wherein said method treats deep vein thrombosis.

20. A method of claim 17 wherein said method treats myocardial infarct.

21. A method of claim 17 wherein said method treats stroke.